Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Xiancheng Wu, Solomon Graf, Ryan Lynch, Chaitra Ujjani, Ted Gooley, Jenna Voutsinas, Heather Rasmussen, Wendy Felder, Kristi Matsumura, Andrew Cowan, Stephen Smith, Mazyar Shadman, Edus Warren, Jonathan Fromm, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5355.

https://doi.org/10.1182/blood-2025-5355

Published: 2025

Journal Articles

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 784.

https://doi.org/10.1182/blood-2025-784

Published: 2025

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2024-206047

Published: 2024

Journal Articles

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, Neena Kennedy, Mengyang Di, Ajay K. Gopal, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Heather Rasmussen, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Stephen D. Smith

Blood (2024) 144 (Supplement 1): 783.

https://doi.org/10.1182/blood-2024-208269

Published: 2024

Journal Articles

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Thomas M Kuczmarski, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Yolanda D Tseng, Hongyan Du, Jacquelin Vandermeer, Alyssa Kelly, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal, Ryan C Lynch

Blood (2024) 144 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2024-208412

Published: 2024

Journal Articles

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2024-206601

Published: 2024

Journal Articles

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Blood (2024) 144 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2024-206512

Published: 2024

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Stephen D Smith, Chaitra S Ujjani, Susan Ottemiller, Melissa Mary Fessel, Bonnie Joy, Jacob DeBell, Joshua Dizon, Ryan Park, Heather Rasmussen, Jacquelin Vandermeer, Jenna M Voutsinas, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2023-174292

Published: 2023

Journal Articles

Comparison of Dietary Intake and Dietary Inflammatory Index in Patients with Chronic Lymphocytic Leukemia By Treatment Status to Cohabitating Controls

Christopher R D'Angelo, Heather Rasmussen, Fang Yu, Sydney A Skupa, Dalia El-Gamal

Blood (2023) 142 (Supplement 1): 6532.

https://doi.org/10.1182/blood-2023-184782

Published: 2023

Journal Articles

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Blood (2023) 142 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2023-179547

Published: 2023

Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Blood (2023) 141 (21): 2576–2586.

https://doi.org/10.1182/blood.2022019254

Published: 2023

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Comparison of Dietary Intake and Dietary Inflammatory Index in Patients with Chronic Lymphocytic Leukemia By Treatment Status to Cohabitating Controls

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only